Skip to main content
. 2020 Sep 10;11:1820. doi: 10.3389/fimmu.2020.01820

Figure 7.

Figure 7

Gal-3 balances cancer malignancy in the early phases of prostate cancer development. In the early phases of disease development and metastasis CSCs, through Gal-3, drive prostate cancer malignancy, and immunosuppression.